Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05974930
Other study ID # 69589
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date October 1, 2023
Est. completion date December 30, 2025

Study information

Verified date July 2023
Source Aristotle University Of Thessaloniki
Contact Georgios Kassimis, MD, PhD
Phone +306936693916
Email gksup@yahoo.gr
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The main goal of the ULTRA-STEMI trial is to investigate the prognostic impact of IVUS-guided PCI in patients with STEMI and correlate IVUS measurements with clinical, procedural, imaging and follow-up outcomes of interest. Study participants will undergo primary PCI as per standardized procedures; IVUS will be performed at baseline, post-intervention and post-optimization. Manual thrombus aspiration will be performed according to clinical indications. The aspirated thrombi will be collected and scanned with micro-computed tomography (micro-CT). Also, angiographic and peri-procedural data will be gathered. Post-PCI instantaneous wave-free ratio (IFR) will also be performed to assess the severity of the residual coronary-artery stenosis, if any. All patients will be followed up for at least12 months for the adjudication of major adverse cardiovascular events.


Description:

The ULTRA-STEMI trial is a prospective investigator-initiated single-centre single-arm observational cohort study aiming to enroll 80 consecutive patients presenting with ST-segment elevation myocardial infarction (STEMI) and undergoing IVUS-guided primary PCI. IVUS will be performed at baseline, post-intervention and post-optimization. Baseline tissue characterization includes the morphological description of culprit lesion plaque and thrombus characteristics as assessed with IVUS. In patients with large thrombus burden, manual thrombus aspiration will be performed according to clinical indications. The aspirated thrombi will be collected and scanned with micro-computed tomography (micro-CT) to correlate IVUS measurements with micro-CT thrombus quantification. Also, angiographic data will be gathered to correlate IVUS measurements with pre-and post-PCI angiographic information. Post-PCI instantaneous wave-free ratio (IFR) will also be performed to assess the severity of the residual coronary-artery stenosis, if any. All patients will be followed up for at least 12 months for the adjudication of major adverse cardiovascular events.The primary endpoint will be target vessel failure at 12 months (defined as a composite of cardiac death, target vessel myocardial infarction and clinically driven target vessel revascularization). The secondary outcomes of interest will be: radiation exposure, contrast use and kidney function effects. Other endpoints include clinical and angiographic outcomes along with post-PCI IVUS, iFR and micro-CT findings.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 80
Est. completion date December 30, 2025
Est. primary completion date October 1, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Patients with acute STEMI undergoing primary PCI within 12 hours of symptom onset according to the 4th universal definition of myocardial infarction. 2. Age >18 years 3. Individuals willing to voluntarily sign the consent and data protection forms before their inclusion in the clinical study. Exclusion Criteria: 1. Patients presenting with cardiogenic shock 2. Patients with a known contraindication for primary PCI 3. Pregnancy 4. Presentation =12 hours after symptom onset

Study Design


Related Conditions & MeSH terms


Intervention

Device:
IVUS imaging for primary PCI guidance
Eagle Eye Platinum Intravascular ultrasound (IVUS) will be used to assess intra-coronary plaque, thrombus or stenosis in patients with STEMI. The device is FDA- and EMA-approved and routinely used in clinical practice. Quantitative and qualitative IVUS parameters will be collected and recorded for all participants to be correlated with clinical, imaging and angiographic outcomes of interest.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Aristotle University Of Thessaloniki

References & Publications (3)

Didagelos M, Pagiantza A, Zegkos T, Zarra K, Angelopoulos V, Kouparanis A, Peteinidou E, Kassimis G, Karvounis H, Ziakas A. Low Molecular Weight Heparin in Improving RAO After Transradial Coronary Catheterization: The LOW-RAO Randomized Study. JACC Cardiovasc Interv. 2022 Aug 22;15(16):1686-1688. doi: 10.1016/j.jcin.2022.05.047. Epub 2022 Jul 27. No abstract available. — View Citation

Groenland FTW, Mahmoud KD, Neleman T, Ziedses des Plantes AC, Scoccia A, Ligthart J, Witberg KT, Nuis RJ, den Dekker WK, Wilschut JM, Diletti R, Zijlstra F, Kardys I, Cummins P, Van Mieghem NM, Daemen J. Tissue characterisation and primary percutaneous coronary intervention guidance using intravascular ultrasound: rationale and design of the SPECTRUM study. Open Heart. 2022 Apr;9(1):e001955. doi: 10.1136/openhrt-2021-001955. — View Citation

Karagiannidis E, Papazoglou AS, Sofidis G, Chatzinikolaou E, Keklikoglou K, Panteris E, Kartas A, Stalikas N, Zegkos T, Girtovitis F, Moysidis DV, Stefanopoulos L, Koupidis K, Hadjimiltiades S, Giannakoulas G, Arvanitidis C, Michaelson JS, Karvounis H, Sianos G. Micro-CT-Based Quantification of Extracted Thrombus Burden Characteristics and Association With Angiographic Outcomes in Patients With ST-Elevation Myocardial Infarction: The QUEST-STEMI Study. Front Cardiovasc Med. 2021 Apr 21;8:646064. doi: 10.3389/fcvm.2021.646064. eCollection 2021. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Rate of "Target vessel failure" at 12 months of follow-up in association with IVUS measurements Follow-up will be obtained using online patient-reported outcome measurements by email or standardized telephone calls at 30 days, 6 months and 12 months after the procedure. Primary follow-up outcome of interest is the composite endpoint of target vessel failure (cardiac death, new-onset heart failure, target vessel myocardial infarction, clinically driven target vessel revascularization or target lesion revascularization). 2 years
Primary All-cause mortality at 12 months of follow-up in association with IVUS measurements Co-primary study outcome will be the investigation of all-cause mortality (i.e., death from any cause) after hospitalization and during follow-up. 2 years
Secondary In-hospital (post-PCI) adverse events in association with IVUS measurements The composite endpoint of in-hospital (post-PCI) adverse events includes: cardiac tamponade, need for CABG, shock, in-hospital mortality, acute kidney failure, bleeding, stroke. 2 years
Secondary Pre-procedural angiographic outcomes in association with IVUS measurements Pre-procedural Thrombolysis in myocardial infarction (TIMI) flow, thrombus burden classification, culprit vessel, number of diseased vessels, and the SYNergy between percutaneous intervention with TAXus DES and cardiac surgery (SYNTAX) score will be recorded and associated with pre-procedural IVUS measurements. Higher SYNTAX score and lower TIMI flow represent greater obstruction in the diseased vessels. 2 years
Secondary Post-procedural angiographic outcomes in association with IVUS measurements Post-procedural TIMI flow, angiographically evident residual thrombus, no-reflow phenomenon, myocardial blush grade, and distal embolization will be recorded and associated with IVUS measurements. 2 years
Secondary Post-PCI iFR measurement in association with IVUS measurements iFR=ratio of distal coronary pressure (Pd) to the aortic pressure (Pa) during an isolated period during diastole. 2 years
Secondary Microtomographic thrombus volume in association with IVUS measurements Micro-CT derived volume of the extracted thrombotic material will be correlated with IVUS measurements. 2 years
Secondary Microtomographic thrombus porosity in association with IVUS measurements Micro-CT derived porosity of the extracted thrombotic material will be correlated with IVUS measurements. 2 years
Secondary Microtomographic thrombus density in association with IVUS measurements Micro-CT derived density of the extracted thrombotic material will be correlated with IVUS measurements. 2 years
Secondary ?umber and type of stents in association with IVUS measurements ?umber and type of stents used will be recorded and associated with IVUS measurements. 2 years
Secondary Stent length and diameter in association with IVUS measurements Stent length and diameter will be recorded and associated with IVUS measurements. 2 years
Secondary Contrast volume in association with IVUS measurements Volume of the contrast used will be recorded and associated with IVUS measurements. 2 years
Secondary Radiation dose in association with IVUS measurements Peri-procedural radiation dose will be recorded and associated with IVUS measurements. 2 years
Secondary Procedural duration in association with IVUS measurements Procedural duration will be recorded and associated with IVUS measurements. 2 years
Secondary Post-PCI stent underexpansion, deformation or malapposition in association with baseline IVUS measurements Stent underexpansion, deformation or malapposition (yes/no) will be recorded and associated with baseline IVUS measurements. 2 years
Secondary Post-PCI edge dissection in association with baseline IVUS measurements Edge dissection (yes/no) will be recorded and associated with baseline IVUS measurements. 2 years
Secondary Post-PCI high plaque burden at stent edges, residual focal lesions or tissue protrusion through the stent struts in association with baseline IVUS measurements High plaque burden at stent edges, residual focal lesions or tissue protrusion through the stent struts (yes/no) will be recorded and associated with baseline IVUS measurements. 2 years
See also
  Status Clinical Trial Phase
Not yet recruiting NCT02871622 - BMX Alpha Registry: a Post-market Registry of the BioMatrix Alpha TM N/A
Completed NCT01325116 - Delayed Educational Reminders in Acute Myocardial Infarction (MI) N/A
Completed NCT01452139 - Pharmacogenetic Approach to Anti-platelet Therapy for the Treatment of ST-segment Elevation Myocardial Infarction (STEMI) Phase 2/Phase 3
Completed NCT01625104 - Randomized Trial of a Quality Improvement Intervention to Decrease D2B Time in Primary PCI for AMI N/A
Completed NCT04023266 - A Pilot Randomized Controlled Trial of Intravenous N-acetyl Cysteine in STEMI Phase 2
Completed NCT02170103 - Microvascular Recovery With Ultrasound in Myocardial Infarction (MRUSMI) Post PCI Trial N/A
Completed NCT03103620 - Safety and Effectiveness Evaluation of COBRA PzF Coronary Stent System: A Post Marketing Observational Registry
Not yet recruiting NCT05975567 - Deploying Novel Imaging Modalities Towards a Three-dimensional (3D) CARDIOvascular PATHology
Enrolling by invitation NCT03328156 - Erectile Dysfunction After Percutaneous Coronary Intervention Versus the Thrombolytic Therapy in Acute ST Elevation Myocardial Infarction N/A
Completed NCT04017169 - No Reflow Phenomenon Incidence and Predictors
Completed NCT03470441 - A Study of Acute Myocardial Infarction Using FDY-5301 Phase 2
Active, not recruiting NCT01433627 - Minimizing Adverse Haemorrhagic Events by TRansradial Access Site and Systemic Implementation of angioX Phase 3
Completed NCT01197742 - Sweetheart-Register: Risk Management of Diabetics With Acute Myocardial Infarction N/A
Terminated NCT03439150 - Resistance STEMI Study N/A
Recruiting NCT03998319 - A Study of Low-dose Intracoronary Thrombolytic Therapy in STEMI (Heart Attack) Patients. Phase 3
Active, not recruiting NCT03102723 - Platelet Inhibition to Target Reperfusion Injury Phase 2
Completed NCT03930589 - Remote Ischemic Conditioning in STEMI to Decrease Infarct Size N/A
Not yet recruiting NCT04912167 - The Effects of Sacubitril-Valsartan vs Enalapril on Left Ventricular Remodeling in ST-elevation Myocardial Infarction Phase 3
Completed NCT02942550 - Methylnaltrexone as a Method to Improve Ticagrelor Uptake in Morphine Treated STEMI Patients Phase 4
Recruiting NCT02604394 - Rheolytic Thrombectomy in Patients With Acute STEMI and Large Thrombus Burden N/A